Related Experiment Video
Updated: Jul 17, 2026
08:01
Semi-Minimal Invasive Method to Induce Myocardial Infarction in Rats and the Assessment of Cardiac Function by an Isolated Working Heart System
Published on: June 11, 2020
Inhaled milrinone: a new alternative in cardiac surgery?
André Y Denault1, Yoan Lamarche, Pierre Couture
1Department of Cardiac Anesthesiology, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada. denault@videotron.ca
Seminars in Cardiothoracic and Vascular Anesthesia
|January 4, 2007
Summary
Inhaled milrinone effectively lowers pulmonary artery pressure without causing systemic hypotension, offering a potential alternative to nitric oxide for respiratory conditions.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Pharmacology
Background:
- Milrinone is a phosphodiesterase 3 inhibitor.
- Intravenous milrinone is used for heart failure.
- Inhaled drug delivery offers targeted lung therapy.
Purpose of the Study:
- To summarize the current knowledge on inhaled milrinone.
- To compare inhaled versus intravenous milrinone administration.
- To assess the potential of inhaled milrinone as an alternative to nitric oxide.
Main Methods:
- Review of existing animal and human studies on inhaled milrinone.
- Analysis of data comparing inhaled and intravenous milrinone effects.
- Evaluation of safety and efficacy parameters, including pulmonary artery pressure and systemic blood pressure.
Main Results:
- Limited studies exist on inhaled milrinone.
- Inhaled milrinone reduces pulmonary artery pressure.
- Systemic hypotension is avoided with inhaled administration.
Conclusions:
- Inhaled milrinone demonstrates efficacy in reducing pulmonary artery pressure.
- The route of administration avoids systemic side effects like hypotension.
- Inhaled milrinone presents a promising alternative to nitric oxide therapy.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
01:25Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...